A 34.79% Potential Upside Amid Robust Revenue Growth
Investors with a keen eye on the healthcare sector may find Glaukos Corporation (NYSE: GKOS) an intriguing opportunity, especially considering its potential upside of 34.79% based on the average target price of $117.50. As a prominent player in the medical devices industry, Glaukos is pioneering innovative therapies for eye disorders, which include glaucoma, corneal issues, and retinal diseases, showcasing a promising growth trajectory.
Glaukos Corporation, headquartered in Aliso Viejo, California, boasts a market capitalization of $5 billion. The company is renowned for its ophthalmic pharmaceuticals and medical technologies, such as the iStent and iDose TR, which are pivotal in treating open-angle glaucoma and ocular…
